Issue of Equity

Investors | December 20, 2021

LONDON, UK. AND NEW YORK, U.S. (20 December 2021). Trellus Health plc (AIM: TRLS), which is commercialising a scientifically validated, resilience-based, connected health solution for chronic condition management, announces that it has issued and allotted 33,333 ordinary shares of  0.06 pence each in the share capital of the Company (“Ordinary Shares”) following an exercise of options. The exercise price was $0.20 per Ordinary Share.

Application has been made to the London Stock Exchange for the new Ordinary Shares to be admitted to trading on AIM. It is expected that admission of the 33,333 new Ordinary Shares to trading on AIM will become effective on, or around, 24 December 2021 (“Admission”).

Upon Admission, the issued Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares of the Company and will trade in the Company’s existing restricted line of Ordinary Shares under the symbol TRLS and ISIN GB00BNNFM402. The Shares may not be offered or sold or otherwise transferred in the absence of registration under the US Securities Act, unless the transaction is exempt from, or not subject, to the registration requirements of the US Securities Act and that resales or reoffers of the Shares made offshore in reliance on Regulation S (of the US Securities Act) may not be offered or sold to, or for the account or benefit of, US Persons during the Distribution Compliance Period. Sales of existing shares to non-US persons made in accordance with Regulation S may continue to be made.  Further information can be found in the Company’s admission document, available via https://trellushealth.com/investors/documents-and-presentations

 

Total voting rights

Following Admission, the Company will have 161,508,333 Ordinary Shares in issue with each share carrying the right to one vote. The Company has no Ordinary Shares held in treasury. The total number of voting rights in the Company following Admission will therefore be 161,508,333.

 

For further information please contact:

 

Trellus Health plc
Monique Fayad, CEO
Julian Baines, Chairman
www.trellushealth.com
Via Walbrook PR
  
Singer Capital Markets (Nominated Adviser & Broker)
Aubrey Powell / Jen Boorer 
Tel: 020 7496 3000
  
Walbrook PR Limited
Paul McManus / Sam Allen
Tel: 020 7933 8780 or trellus@walbrookpr.com
Mob: 07980 541 893 / 07502 558 258
  

Media Inquiries

For Media Inquiries contact media@trellushealth.com for Trellus Health